Menu
GWAS Study

Two susceptibility loci identified for prostate cancer aggressiveness.

Berndt SI, Wang Z, Yeager M et al.

25939597 PubMed ID
GWAS Study Type
22943 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

BS
Berndt SI
WZ
Wang Z
YM
Yeager M
AM
Alavanja MC
AD
Albanes D
AL
Amundadottir L
AG
Andriole G
BF
Beane Freeman L
CD
Campa D
CG
Cancel-Tassin G
CF
Canzian F
CJ
Cornu JN
CO
Cussenot O
DW
Diver WR
GS
Gapstur SM
GH
Grönberg H
HC
Haiman CA
HB
Henderson B
HA
Hutchinson A
HD
Hunter DJ
KT
Key TJ
KS
Kolb S
KS
Koutros S
KP
Kraft P
LM
Le Marchand L
LS
Lindström S
MM
Machiela MJ
OE
Ostrander EA
RE
Riboli E
SF
Schumacher F
SA
Siddiq A
SJ
Stanford JL
SV
Stevens VL
TR
Travis RC
TK
Tsilidis KK
VJ
Virtamo J
WS
Weinstein S
WF
Wilkund F
XJ
Xu J
LZ
Lilly Zheng S
YK
Yu K
WW
Wheeler W
ZH
Zhang H
SJ
Sampson J
BA
Black A
JK
Jacobs K
HR
Hoover RN
TM
Tucker M
CS
Chanock SJ
Chapter II

Abstract

Summary of the research findings

Most men diagnosed with prostate cancer will experience indolent disease; hence, discovering genetic variants that distinguish aggressive from nonaggressive prostate cancer is of critical clinical importance for disease prevention and treatment. In a multistage, case-only genome-wide association study of 12,518 prostate cancer cases, we identify two loci associated with Gleason score, a pathological measure of disease aggressiveness: rs35148638 at 5q14.3 (RASA1, P=6.49 × 10(-9)) and rs78943174 at 3q26.31 (NAALADL2, P=4.18 × 10(-8)). In a stratified case-control analysis, the SNP at 5q14.3 appears specific for aggressive prostate cancer (P=8.85 × 10(-5)) with no association for nonaggressive prostate cancer compared with controls (P=0.57). The proximity of these loci to genes involved in vascular disease suggests potential biological mechanisms worthy of further investigation.

4,600 European ancestry cases, 2,941 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

22943
Total Participants
GWAS
Study Type
Yes
Replicated
7,779 European ancestry cases, 7,623 European ancestry controls
Replication Participants
European
Ancestry
U.S.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.